Publications by authors named "Jacopo Venturini"
Colorectal cancer (CRC) represents a global health threat, standing as the second leading cause of cancer-related death worldwide. Targeted therapies brought new hope for the metastatic stage, which historically bore a very poor prognosis. Human epidermal growth receptor 2 (HER2) overexpression concerns about 5 % of the metastatic CRC (mCRC) patients, including both gene amplifications and point mutations.
View Article and Find Full Text PDFArticle Synopsis
- Management of metastatic colorectal cancer (mCRC) involves a continuum of care, primarily utilizing options like trifluridine/tipiracil and regorafenib after patients progress on standard therapies.
- Fruquintinib, a selective inhibitor for VEGFR-1, -2, and -3, has shown significant anti-tumor effects and was approved for treatment in China based on the successful phase III FRESCO trial.
- The subsequent FRESCO-2 trial validated these findings in various regions, showing fruquintinib improves overall survival in a heavily pretreated population and highlighting the need for identifying patients who may benefit most from this therapy.
Immunotherapy is an ever-expanding field in lung cancer treatment research. Over the past two decades, there has been significant progress in identifying immunotherapy targets and creating specific therapeutic agents, leading to a major paradigm shift in lung cancer treatment. However, despite the great success achieved with programmed death protein 1/ligand 1 (PD-1/PD-L1) monoclonal antibodies and with anti-PD-1/PD-L1 plus anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4), only a minority of lung cancer patients respond to treatment, and of these many subsequently experience disease progression.
View Article and Find Full Text PDFArticle Synopsis
- About half of metastatic colorectal cancers have RAS mutations, which are important for understanding prognosis and developing targeted therapies, particularly focusing on KRAS hotspot mutations.
- A study examined the association of KRAS mutations with patient characteristics, prognosis, and response to antiangiogenic treatments using data from 183 patients with advanced CRC.
- Results showed specific KRAS mutations linked to certain metastatic patterns and demographics, with KRAS exon 4 mutations associated with significantly longer overall survival compared to other mutations.